Resultados de procura - David Chiron

  • Mostrando 1 - 9 Resultados de 9
Limitar resultados
  1. 1
    Toll-like receptors: lessons to learn from normal and malignant human B cells

    Toll-like receptors: lessons to learn from normal and malignant human B cells por David Chiron, Isabelle Bekeredjian‐Ding, Catherine Pellat‐Deceunynck, Régis Bataille, Gaëtan Jégo

    Publicado 2008
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker

    BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker por Benoît Tessoulin, Antonin Papin, Patricia Gomez‐Bougie, Céline Bellanger, Martine Amiot, Catherine Pellat‐Deceunynck, David Chiron

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

    Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma por David Chiron, Christelle Dousset, Carole Brosseau, Cyrille Touzeau, Sophie Maïga, Philippe Moreau, Catherine Pellat‐Deceunynck, Steven Le Gouill, Martine Amiot

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Induction of prolonged early G<sub>1</sub>arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1

    Induction of prolonged early G<sub>1</sub>arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1 por David Chiron, Peter Martin, Maurizio Di Liberto, Xiangao Huang, Scott Ely, Brian J. Lannutti, John P. Leonard, Christopher E. Mason, Selina Chen‐Kiang

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

    Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells por Sylvanie Surget, David Chiron, Patricia Gomez‐Bougie, Géraldine Descamps, Emmanuelle Ménoret, Régis Bataille, Philippe Moreau, Steven Le Gouill, Martine Amiot, Catherine Pellat‐Deceunynck

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

    Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways por Benoît Tessoulin, Agnès Moreau‐Aubry, Géraldine Descamps, Patricia Gomez‐Bougie, Sophie Maïga, Alban Gaignard, David Chiron, Emmanuelle Ménoret, Steven Le Gouill, Philippe Moreau, Martine Amiot, Catherine Pellat‐Deceunynck

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

    Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma por David Chiron, Céline Bellanger, Antonin Papin, Benoît Tessoulin, Christelle Dousset, Sophie Maïga, Philippe Moreau, Julie Esbelin, Valérie Trichet, Selina Chen‐Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat‐Deceunynck

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

    Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial por Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet‐Milin, Sylviane Ragot, Céline Bossard, Nathalie Nadal, Charles Herbaux, Benoît Tessoulin, Emmanuelle Tchernonog, Cédric Rossi, Rory McCulloch, Thomas Gastinne, Mary Callanan, Simon Rule

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

    Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma por David Chiron, Maurizio Di Liberto, Peter Martin, Xiangao Huang, Jeff P. Sharman, Pedro Blecua, Susan Mathew, Priyanka Vijay, Ken Eng, Siraj M. Ali, Amy J. Johnson, Betty Chang, Scott Ely, Olivier Elemento, Christopher E. Mason, John P. Leonard, Selina Chen‐Kiang

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: